On May 2, 2025, RBC Capital analyst Gregory Renza maintained his "Outperform" rating on Amgen (AMGN, Financial). Despite the unchanged rating, Renza lowered the price target from $324.00 USD to $320.00 USD, marking a decrease of approximately 1.23% in the target price.
This adjustment reflects a cautious outlook for Amgen (AMGN, Financial) while still indicating a positive performance expectation relative to the market. The price target adjustment appears to be a strategic decision by RBC Capital, aiming to align future price expectations with current market conditions.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 25 analysts, the average target price for Amgen Inc (AMGN, Financial) is $319.08 with a high estimate of $400.00 and a low estimate of $185.00. The average target implies an upside of 13.45% from the current price of $281.27. More detailed estimate data can be found on the Amgen Inc (AMGN) Forecast page.
Based on the consensus recommendation from 33 brokerage firms, Amgen Inc's (AMGN, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Amgen Inc (AMGN, Financial) in one year is $347.28, suggesting a upside of 23.47% from the current price of $281.265. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Amgen Inc (AMGN) Summary page.
